Stemcentrx is a biotech unicorn that aims to create novel cancer therapeutics by targeting cancer stem cells. 

Valuation: $5 Billion
Patents: 23
Pending Patents: 2
Trademarks: 2
Competitors: Juno Therapeutics, Oncomed Pharmaceuticals, AbbVie Inc

Most of Stemcentrx's patents involve anti-DLL3 antibodies. Some examples follow: 

• US9089617B2: Anti-DLL3 antibody drug conjugates

• US9090683: Methods of Detection, Diagnosis, and Monitoring Using Anti-DLL3 Antibodies

• US9155803: ANTI-DLL3 ANTIBODY DRUG CONJUGATES AND METHODS OF USE

• US9107961: Anti-DLL3 Antibody Drug Conjugates for Treating Cancer

• US9089615: ANTI-DLL3 ANTIBODIES

Sources:
http://blogs.wsj.com/venturecapital/2015/09/16/peter-thiel-backed-stemcentrx-emerges-with-5-billion-valuation/
http://assignment.uspto.gov/#/search?q=STEM%20CENTRX%20INC&sort=patAssignorEarliestExDate%20desc%2C%20id%20desc&synonyms=false
https://patents.google.com/patent/US9089617B2/en